mynth
← DATABASE
05/2017

ELITECH GROUP acquired by PAI PARTNERS

FRANCE Life Sciences / Medical Devices / Diagnostic Equipment EV €300–700M

Context

Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector. Rather than a simple portfolio addition, this move represents a calculated bet on the structural transition toward decentralized laboratory automation and precision pathology.

Previously, Elitech Group had completed the acquisition of Vital Diagnostics in 2013 as part of its consolidation strategy.

ELITECH GROUP, which reported an EBITDA margin of [members only] in 2016, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

ELITechGroup operates as a premier technology organization dedicated to the engineering and distribution of specialized in-vitro diagnostic (IVD) systems and reagents. The entity’s business model is centered on a proprietary framework of molecular diagnostic (MDx) platforms, notably the InGenius® and BeGenius® systems, which offer fully automated sample-to-result workflows. Its value proposition is anchored in technical operational depth, providing a high-margin recurring revenue stream with over 80% of sales derived from specialized consumables and PCR test assays for infectious diseases. Strategically, the firm focuses on serving medium-sized hospitals and clinical laboratories, offering a niche alternative to large-scale commodity diagnostic providers. By maintaining an extensive IP portfolio and a specialized focus on viral and bacterial pathogen detection, the organization ensures a mission-critical role in clinical decision-making across Europe and Latin America. The entity prioritizes technical innovation and global regulatory compliance to facilitate the structural advancement of precision medicine.

Ent. Value

€300–700M

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

10x–18x

EV / EBIT

Above 20x

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2016
€100–200M
€10–30M
€5–25M
2015
€100–200M
€10–30M
€5–25M

Other operations with ELITECH GROUP

Other operations with ELITECH GROUP

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
DateAcquirerTargetCountrySector
05/2024BRUKERELITECH GROUPFRANCEDiagnostic Equipment
01/2013ELITECH GROUPVITAL DIAGNOSTICSUNITED STATESDiagnostic Equipment

REFERENCES

Valuation range: EV €300–700M

Revenue range: €100–200M

EBITDA range: €10–30M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ELITECH GROUP by PAI PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: pai partners